Mira Pharma selects neuropathic pain for Ketamir-2, submits pre-IND request to FDA

MIRA PHARMACEUTICALS, INC.

Selected neuropathic pain as primary indication for oral ketamine analog Ketamir-2.
Submitted pre-IND meeting request to FDA; meeting expected October 2024.
Plans to begin human trials in Q1 2025 following IND submission.
No financial details or trial data disclosed in this filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.